Jessica Dooley

Nathan, QLD, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

Journal: Trials
Published: August 27, 2024

Disruption of IL-17-mediated immunosurveillance in the respiratory mucosa results in invasive Streptococcus pyogenes infection.

Disruption of IL-17-mediated immunosurveillance in the respiratory mucosa results in invasive Streptococcus pyogenes infection.

Journal: Frontiers in immunology
Published: December 07, 2023

Streptolysin O Deficiency in Streptococcus pyogenes M1T1 covR/S Mutant Strain Attenuates Virulence in In Vitro and In Vivo Infection Models.

Streptolysin O Deficiency in Streptococcus pyogenes M1T1 covR/S Mutant Strain Attenuates Virulence in In Vitro and In Vivo Infection Models.

Journal: mBio
Published: February 06, 2023

A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.

A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.

Journal: Nature communications
Published: July 21, 2021

Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes.

Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes.

Journal: mBio
Published: February 24, 2021

Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.

Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.

Journal: Scientific reports
Published: October 14, 2020

Erratum: Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Erratum: Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Journal: NPJ vaccines
Published: September 18, 2020

M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Journal: NPJ vaccines
Published: April 07, 2020
Showing 1-8 of 8

Last Updated: 09/26/2026